Differences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912.
about
Bifeprunox versus placebo for schizophreniaUpdate on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor AntagonismUnique Effects of Acute Aripiprazole Treatment on the Dopamine D2 Receptor Downstream cAMP-PKA and Akt-GSK3β Signalling Pathways in RatsAripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data.Tetrabenazine is neuroprotective in Huntington's disease mice.The effects of additional treatment with terguride, a partial dopamine agonist, on hyperprolactinemia induced by antipsychotics in schizophrenia patients: a preliminary studyComparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties.Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.Effects of (-)-OSU6162 and ACR16 on motor activity in rats, indicating a unique mechanism of dopaminergic stabilization.Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?Aripiprazole and Haloperidol Activate GSK3β-Dependent Signalling Pathway Differentially in Various Brain Regions of Rats.A review of the safety and tolerability of aripiprazole.Drugs in development for the treatment of schizophrenia.Aripiprazole treatment for patients with schizophrenia: from acute treatment to maintenance treatment.Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model.Bifeprunox versus placebo for schizophrenia.Aripiprazole in the Treatment of Irritability in Children and Adolescents with Autism Spectrum Disorder in Japan: A Randomized, Double-blind, Placebo-controlled Study.The relationship between glycine transporter 1 occupancy and the effects of the glycine transporter 1 inhibitor RG1678 or ORG25935 on object retrieval performance in scopolamine impaired rhesus monkey.The pridopidine paradox in Huntington's disease.An open-label extension long-term study of the safety and efficacy of aripiprazole for irritability in children and adolescents with autistic disorder in Japan.Pharmacokinetics and Safety of Brexpiprazole Following Multiple-Dose Administration to Japanese Patients With Schizophrenia.Aripiprazole Increases the PKA Signalling and Expression of the GABAA Receptor and CREB1 in the Nucleus Accumbens of Rats.Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington's Disease.
P2860
Q24186774-8A85117D-9DFF-41CF-957B-4442E11F9F73Q28084069-7AD0490B-8501-4289-BC52-8E9EEF3B5C43Q28546441-DE30B6E0-033F-4BC7-A709-9E31F83C285BQ33799660-16823B05-B538-4FFB-A895-5230D9A34942Q33863426-84D381EA-42ED-49D2-B60B-0771679F5EBDQ34110039-1865F840-BD52-4119-8B63-9DEAD95C1B2AQ34169978-302704F7-3E0F-44F0-A22F-2F6E9DF3E954Q34274859-F2C7C41A-D944-4361-8D82-A0AF3485C327Q34763003-384D7E2B-A94A-4266-AFC4-FE6860AECBA5Q35012574-F43D6D4A-520E-4E01-AB54-824EEB1CD9FEQ36846918-B6877A79-A1EE-4C5A-BFDA-4A9190BA1BD6Q37510958-9D89957E-EE56-4AB7-9B28-8518222B3D68Q37546125-5892BA09-A57F-4BDF-B059-C248298F6D20Q37947687-E93AF2C2-E105-4947-9403-1FB0841F03A7Q38861728-3D3F3532-059E-4AFD-8F39-1B25D14261B7Q38978909-6CFDA941-BFAD-43CF-BD37-3E421C8AB372Q42365528-3B10B565-9B79-4476-AA35-A86FD3A93C8FQ44153709-9794268F-48E9-4720-9C50-3F5112F31CD2Q45294030-13B015A2-E167-4EF5-BA19-610DA93FFCACQ47615376-58293946-2E9D-4AB9-A6C7-0B48635CCC3CQ47814439-BBC892CA-FB37-4F3A-9A2F-EEFD38D76B88Q48234174-07D6431C-9B40-48B6-9BB2-445591FDB7F1Q52685691-990C39DF-594E-44D5-A157-30DE76E3D506
P2860
Differences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Differences in agonist/antagon ...... e, bifeprunox and SDZ 208-912.
@en
Differences in agonist/antagon ...... e, bifeprunox and SDZ 208-912.
@nl
type
label
Differences in agonist/antagon ...... e, bifeprunox and SDZ 208-912.
@en
Differences in agonist/antagon ...... e, bifeprunox and SDZ 208-912.
@nl
prefLabel
Differences in agonist/antagon ...... e, bifeprunox and SDZ 208-912.
@en
Differences in agonist/antagon ...... e, bifeprunox and SDZ 208-912.
@nl
P2093
P1476
Differences in agonist/antagon ...... e, bifeprunox and SDZ 208-912.
@en
P2093
Arlene Stark
Hisashi Kitagawa
Robert A Forbes
Robert D McQuade
Tetsuro Kikuchi
Yoshihiro Tadori
P304
P356
10.1016/J.EJPHAR.2007.07.031
P407
P577
2007-08-10T00:00:00Z